News Sentiment

CNTX sentiment intelligence

Context Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.65 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.1% over one week, -53.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -0.1% Price digesting
Trend fit Trend inactive -53.0% over four weeks
Fair value -53.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 30
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 8
Stock Titan 8
GlobeNewswire 5
simplywall.st 4
www.marketscreener.com 3
Quartr 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 12
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
TradingView Direct company coverage

Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9

This article provides financial information for Context Therapeutics, Inc. (DUS:6K9), focusing on its enterprise value to EBITDA forward. It includes a table displaying the period, value, and percentage change for this metric, noting that the data was "Made by humans." The page a

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 03:11
Source
TradingView
Quartr Direct company coverage

Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary

Context Therapeutics (CNTX) presented key strategic and pipeline priorities at the Leerink Global Healthcare Conference 2026, focusing on T-cell engagers for solid tumors, particularly to address ADC resistance. Their Claudin 6 program is targeting platinum-resistant, ADC-exposed

Tone
Positive 66/100
Event
Market update
Published
11 Jul 2026 15:11
Source
Quartr
GlobeNewswire Direct company coverage

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Inc. (Nasdaq: CNTX) announced an inducement grant of a non-qualified stock option award to a new employee for 146,000 shares of common stock. This grant was made outside the company's 2021 Long-Term Performance Incentive Plan, as permitted by Nasdaq Listing R

Tone
Positive 64/100
Event
Market update
Published
11 Jul 2026 14:10
Source
GlobeNewswire
Quartr Direct company coverage

Context Therapeutics (CNTX) Proxy filing Summary

Context Therapeutics (CNTX) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for June 24, 2026. Shareholders will vote on director elections, auditor ratification, and a significant increase in authorized common stock from 200 million to

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 09:40
Source
Quartr
Stock Titan Direct company coverage

New Context Therapeutics hire receives 146,000-share stock option at $0.70

Context Therapeutics (Nasdaq: CNTX) granted a new employee a non-qualified stock option to purchase 146,000 shares of common stock at an exercise price of $0.70 per share. This inducement award was granted under Nasdaq Listing Rule 5635(c)(4) and falls outside the company's 2021

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes

Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000 and broad-market Russell 3000 Indexes, effective June 26, 2026. This inclusion is significant as these indexes are widely used benchmarks by

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 09:11
Source
www.marketscreener.com
Moomoo Direct company coverage

Context Therapeutics Joins Russell 2000, Russell 3000 Indexes

Context Therapeutics (Nasdaq: CNTX) has announced its inclusion in the Russell 2000 and Russell 3000 Indexes, effective after the U.S. markets opened on June 28, 2024. This inclusion positions the company among the largest U.S. stocks, boosting its visibility and potentially attr

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 01:12
Source
Moomoo
GlobeNewswire Direct company coverage

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000® and the broad-market Russell 3000® Indexes. This move was effective at the close of U.S. equity markets on June 26, 2026. These indexes are

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 01:12
Source
GlobeNewswire
Investing.com Nigeria Direct company coverage

Context Therapeutics stock rises on Russell index inclusion By Investing.com

Context Therapeutics Inc. (NASDAQ:CNTX) shares rose by 2.7% in after-hours trading following its inclusion in the Russell 2000 and Russell 3000 indexes on June 26, 2026. This inclusion is expected to increase institutional ownership as index funds adjust their portfolios. The com

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 20:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Context Therapeutics joins Russell 2000 and 3000 indexes

Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, announced its inclusion in the small-cap Russell 2000® and the broad-market Russell 3000® Indexes. This addition, effective June 26, 2026, aligns CNTX with major U.S. equity benchmarks, potentially b

Tone
Positive 88/100
Event
Market update
Published
06 Jul 2026 19:40
Source
Stock Titan
TradingView Direct company coverage

Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9

This article displays the "Diluted net income available to common stockholders" for Context Therapeutics, Inc. (DUS:6K9) on the TradingView platform. It provides a placeholder for the period, value, and change in this financial metric, indicating that the data itself would be pre

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 05:41
Source
TradingView
www.marketscreener.com Direct company coverage

Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index

Context Therapeutics Inc. (NasdaqCM:CNTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, highlighting increased visibility for the biopharmaceutical company. Context Therapeutics focuse

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 12:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark

Context Therapeutics Inc. (NasdaqCM: CNTX) has been included in the Russell 3000E Growth Benchmark. This addition reflects the company's growth trajectory within the biotechnology and medical research sector. The article also provides a company profile, recent news, and various f

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 08:40
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9

The article presents the "Enterprise value to EBITDA forward" metric for Context Therapeutics, Inc. (MUN:6K9) on the Munich Stock Exchange. It indicates that the market was closed with no trades recorded at the time of publication. The data is provided by FactSet Research Systems

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Context Therapeutics Inc. – NASDAQ:CNTX

This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its forward price-to-earnings ratio. It indicates that the company's financial information is available through TradingView, utilizing market data from ICE Data Services an

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 14:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX

This article provides financial data for Context Therapeutics Inc. (NASDAQ: CNTX), specifically focusing on its Price to Book Forward value. The content is presented within the TradingView platform, offering various financial tools and market data services.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M

Context Therapeutics (NASDAQ: CNTX) announced that its stockholders approved an amendment to increase the authorized common shares from 200 million to 300 million at their annual meeting on June 24, 2026. This decision provides the company with greater flexibility for future equi

Tone
Neutral 50/100
Event
Regulatory and legal
Published
26 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Context Therapeutics (CNTX) receives 45,000 stock options award

Context Therapeutics Inc. (CNTX) director Karen L. Smith was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company’s 2027 annual meeting, contingent on her continue

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576

Context Therapeutics Inc. director Stacey Jennifer Evans was granted 45,000 stock options at an exercise price of $0.576 per share. This compensation-related grant will vest on the earlier of June 24, 2027, or the company’s 2027 annual meeting, contingent on her continued service

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

Context Therapeutics (CNTX) director Linda West awarded 45K stock options

Context Therapeutics director Linda West was granted 45,000 stock options to acquire common stock at an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company’s 2027 annual meeting, contingent on her co

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576

Context Therapeutics Inc. director Andy Pasternak was granted 45,000 stock options with an exercise price of $0.576 per share, expiring on June 23, 2036. The options will vest on the earlier of June 24, 2027, or the company's 2027 annual meeting, dependent on his continued servic

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX)

This article provides an in-depth financial overview of Context Therapeutics Inc. (NASDAQ: CNTX), including its current stock price, historical performance, analyst forecasts, and key financial metrics like market capitalization and upcoming earnings reports. It also answers freq

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Context Therapeutics Inc. – NASDAQ:CNTX

This article displays the "Price to sales forward" data for Context Therapeutics Inc. (NASDAQ: CNTX) on the TradingView platform. The content is primarily a data presentation, indicating the period, value, and change percentage for this financial metric, with a note that the mark

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 03:09
Source
TradingView